Pulmonary tuberculosis with primary drug resistant mycobacterium tuberculosis -treatment outcomes Source: Eur Respir J 2004; 24: Suppl. 48, 657s Year: 2004
Paradoxical reactions in non-HIV tuberculosis presenting as endobronchial obstruction Source: Eur Respir Rev 2009; 18: 295-299 Year: 2009
Treatment of TB Source: Eur Respir Mon 2012; 58: 154-166 Year: 2012
Development of mycobacterium tuberculosis additional drug resistance during chemotherapy of disseminated pulmonary tuberculosis Source: Eur Respir J 2007; 30: Suppl. 51, 663s Year: 2007
Clinical and operational value of the extensively drug-resistant tuberculosis definition Source: Eur Respir J 2007; 30: 623-626 Year: 2007
Predictors of poor treatment outcome in multi- and extensively drug-resistant pulmonary TB Source: Eur Respir J 2009; 33: 1085-1094 Year: 2009
The WHO strategy for TB control and elimination Source: Eur Respir Mon 2012; 58: 242-253 Year: 2012
New method of treatment of MDR destructive pulmonary tuberculosis Source: Eur Respir J 2003; 22: Suppl. 45, 527s Year: 2003
Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis Source: Eur Respir J 2016; 47: 564-574 Year: 2016
Bedaquiline in the treatment of multi-drug resistant non-tuberculous mycobacteria soft tissue infections: a case series Source: Virtual Congress 2021 – Advances in diagnosis, treatment and clinical management of nontuberculous mycobacterial disease Year: 2021
Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases Source: Eur Respir J 2008; 31: 1155-1159 Year: 2008
Drug resistance of Mycobacterium tuberculosis isolated from tuberculosis inflammatory foci Source: Eur Respir J 2005; 26: Suppl. 49, 654s Year: 2005
Susceptibility of Mycobacterium tuberculosis strains to fluoquinolones, obtained from chronic patients with multidrug resistant pulmonary tuberculosis Source: Eur Respir J 2001; 18: Suppl. 33, 315s Year: 2001
Results of drug susceptibility testing of Mycobacterium tuberculosis isolated from sputum and surgical material from pulmonary tuberculosis patients Source: Virtual Congress 2020 – Multidrug-resistant tuberculosis Year: 2020
Efficacy and safety of linezolid for the treatment of multidrug resistant tuberculosis (MDR-TB) and disease by non tuberculous mycobacteria (NTM) Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011
Detection of isoniazid or rifampin resistant Mycobacterium tuberculosis in patients with cavity and previously treated for tuberculosis - usefulness of rapid drug susceptibility test with sputum samples by reverse hybridization assay Source: Annual Congress 2005 - Resistant and multidrug resistant tuberculosis Year: 2005
Determination of drug susceptibility of Mycobacterium tuberculosis through mycolic acid analysis with HPLC technique - comparison to the conventional methods Source: Annual Congress 2005 - Management of tuberculosis pulmonary, extrapulmonary peculiarities Year: 2005
Drug resistance profiles of mycobacterium tuberculosis isolates in MDR pulmonary tuberculosis from a high burden developing country Source: Annual Congress 2008 - The challenge of multidrug-resistant tuberculosis Year: 2008
Artificial pneumothorax in the treatment of multi drug resistant tuberculosis (MDR TB) Source: Eur Respir J 2006; 28: Suppl. 50, 586s Year: 2006
Surgical treatment of patients with disseminated destructive multidrug resistant lung tuberculosis Source: Eur Respir J 2005; 26: Suppl. 49, 489s Year: 2005